Prognostic value of neutrophil-lymphocyte ratio in first line treatment for metastatic pancreatic adenocarcinoma

Rho, Young Soo; Ranger, Jill J.; Hamalova, Sabina; Barrera, Ivan; Mamo, Aline; Batist, Gerald; Kavan, Petr

doi:10.1093/annonc/mdx369.137

Search citation statements

Order By: Relevance

Paper Sections

Select...

Results1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Systemic inflammation ratios, such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and systemic immune inflammation index (SII), reflect the antitumor inflammation capacity of the host and are of prognostic value in PDAC patients [72,73,74]. One study, by Gao et al, investigated the role of the NLR and PLR as a predictive marker in 122 LAPC and metastatic patients, most of whom received gemcitabine treatment.…”

Section: Resultsmentioning

confidence: 99%

Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients

Sijde

Vietsch

Mustafa

et al. 2019

Cancers

View full text Add to dashboard Cite

Pancreatic cancer is a lethal disease with increasing incidence. Most patients present with advanced disease, for which palliative systemic chemotherapy is the only therapeutic option. Despite improved median survival rates with FOLFIRINOX or gemcitabine chemotherapy compared to the best supportive care, many individual patients may not benefit from chemotherapy. Biomarkers are needed to predict who will benefit from chemotherapy and to monitor a patient’s response to chemotherapy. This review summarizes current research and future perspectives on circulating biomarkers for systemic chemotherapy response.

show abstract

Section: Resultsmentioning

confidence: 99%